SIRION Biotech presenting advanced viral vectors and BOOSTER technology at ELRIG Drug Discovery ’16
Press Release | SIRION Biotech GmbH
OCTOBER 10, 2016
Martinsried, Germany: – Viral technology specialist SIRION Biotech will be returning to ELRIG for its 10th Anniversary Drug Discovery (ELRIG-DD16) conference in Liverpool, UK (October 13th-14th).
The company will be posting its latest insights and advances on its LV, AAV and AV viral vector technologies along with presentations on its advanced vector engineering platform VariCHECK, optimized and re-targeted viral vectors for cell-based therapy as well as research- and clinical grade transduction enhancer LentiBOOSTTM to efficiently transduce primary and hard to target cells.
SIRION’s team will include Dr. Franziska Ruf, Key Accounts Manager for Europe and Dr. Cristina-Ileana Ureche, newly appointed Key Account Manager for Asia.
SIRION is inviting all ELRIG-DD16 delegates to contact the company and set up face-to-face meetings with Dr. Ruf or Dr. Ureche during the conference in Liverpool, UK.
Dr. Franziska Ruf, who will present the poster on VariCHECK, commented:
“Why do I care about viral vectors? Simply because engineered viral vectors are not only perfect tools for functional gene analyses and target research but also transform our understanding of disease, becoming new innovative medicines. ”
“SIRION has been a participant at the ELRIG Drug Discovery conferences for several years now. This is an excellent platform to share our knowledge with fellow scientists and company representatives working in cell based research areas like early drug discovery, gene/cell-based therapy and regenerative medicine ,” said Dr. Ruf.
“We’ll be able to show how in gene therapy we are now achieving the highest LV and AAV T-cell transduction rates on the market and how we are using leading vector engineering and capsid optimization to increase tissue specificity and improve immunogenic profile,” added Dr. Cristina-Ileana Ureche.
About SIRION Biotech
In business since 2007 and based near Munich in Germany, SIRION BIOTECH is Europe’s leading commercial supplier of tailored viral vectors used for genetic research, clinical target validation, gene therapy and vaccination studies.
SIRION’s mission is to change the paradigm for viral vector supplies, with its ability to develop and supply all common viral vector types (adenovirus, lentivirus and AAV) in highest quality within a matter of weeks.
The company also offers a full range of virus related products and services, ranging from transduction enhancer agents to fully customized cell models including the transformative RNAiONE™ knockdown validation platform.
With this comprehensive viral vector portfolio, SIRION offers a suitable option for almost any preclinical in vitro and in vivo application.
About ELRIG DD16
The European Laboratory Research & Innovation Group (ELRIG) is a UK-based not-for-profit organization serving the needs of the drug discovery and life science communities across Europe. ELRIG’s flagship event, “Drug Discovery” now attracts more than 1,300 delegates, making it the biggest conference of its kind in Europe.
The 10th anniversary Drug Discovery ’16 is a two-day event, opening October 13 at the Echo Arena (ACC) in Liverpool. The conference will feature more than 50 speakers over six session tracks focusing on Innovations in Chemistry, Oncology & Immunology, Innovations in Predictive & Translational Models, Assay Development, Screening & Emerging Technologies, Cells and Genes in Therapy and Diagnostics and Target Identification & Validation. The conference will also feature an exhibition, as well as a new feature, interactive Core Technologies Workshops & Vendor Tutorials.
More information at: http://elrig.org/portfolio/drug-discovery-2016/
Dr. Franziska Ruf; Manager, Key Accounts Europe, SIRION Biotech GmbH
Click on SIRION Biotech presenting advanced viral vectors and BOOSTER technology at ELRIG Drug Discovery ’16 for other information.
Click on SIRION to contact the company directly.